[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fc3zJMLg0twsMeA9PLYpdAbBA8qEzZ4p0QO8KzTD8hFo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":8,"truncated":9,"activeTrials":10,"phase3Count":11,"totalEnrollment":12,"activePrograms":13,"nonDrugCount":14,"topConditions":15,"upcomingReadouts":36,"phaseBuckets":76,"rows":83},"AdventHealth",[4,6,7],"AdventHealth Translational Research Institute","AdventHealth University",167,false,56,2,22161,8,141,[16,19,21,23,26,28,31,34],{"name":17,"count":18},"Obesity",12,{"name":20,"count":13},"Pancreatic Cancer",{"name":22,"count":13},"Type 2 Diabetes",{"name":24,"count":25},"Diabetes",6,{"name":27,"count":25},"Stress",{"name":29,"count":30},"Pancreatic Neoplasms",5,{"name":32,"count":33},"Pancreatic Neoplasm",4,{"name":35,"count":33},"Burnout",[37,42,46,51,56,61,66,71],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT02817659","To Determine Tolerability to Glucagon Infusion in Obese Subjects","2017-01-13","Glucagon",{"nctId":43,"briefTitle":44,"date":45,"intervention":41},"NCT03139305","Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects","2018-02-14",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05662865","Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers","2024-07-23","SGLT2 inhibitor",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06631521","Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","2026-06","Darolutamide",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07357376","Evaluating Suzetrigine for Pain Control Following TKA","2026-07-01","Suzetrigine",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06617481","PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","2027-09-05","18F-rhPSMA-7.3",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07485803","A RCT Using Methadone in the Management of Post-Operative Pain in Total Knee Replacement","2028-04","Methadone",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07421518","Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors","2030-04","SGLT-2 inhibitor",[77,78,79,80,81,82],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[84,108,130,153,173,215,238,256,277,308,336,354,377,400,428,460,478,496,514,532,550,568,586,615,640,658,684,710,735,760,778,804,822,840,864,890,917,935],{"intervention":70,"totalTrials":85,"cells":86},1,{"EARLY_PHASE1":87,"PHASE1":90,"PHASE2":92,"PHASE3":94,"PHASE4":96,"NA":106},{"trials":88,"activeCount":89},[],0,{"trials":91,"activeCount":89},[],{"trials":93,"activeCount":89},[],{"trials":95,"activeCount":89},[],{"trials":97,"activeCount":85,"soonestReadout":69},[98],{"nctId":67,"briefTitle":68,"status":99,"phases":100,"primaryCompletion":69,"completion":101,"start":54,"enrollment":102,"conditions":103,"interventions":105},"NOT_YET_RECRUITING",[81],"2028-06",192,[104],"Total Knee Arthroplasty",[70],{"trials":107,"activeCount":89},[],{"intervention":60,"totalTrials":85,"cells":109},{"EARLY_PHASE1":110,"PHASE1":112,"PHASE2":114,"PHASE3":116,"PHASE4":126,"NA":128},{"trials":111,"activeCount":89},[],{"trials":113,"activeCount":89},[],{"trials":115,"activeCount":89},[],{"trials":117,"activeCount":85,"soonestReadout":59},[118],{"nctId":57,"briefTitle":58,"status":99,"phases":119,"primaryCompletion":59,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},[80],"2026-08-01","2026-03-01",210,[124],"Postoperative Pain Following Knee Arthroplasty",[60],{"trials":127,"activeCount":89},[],{"trials":129,"activeCount":89},[],{"intervention":65,"totalTrials":85,"cells":131},{"EARLY_PHASE1":132,"PHASE1":134,"PHASE2":136,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":133,"activeCount":89},[],{"trials":135,"activeCount":89},[],{"trials":137,"activeCount":85,"soonestReadout":64},[138],{"nctId":62,"briefTitle":63,"status":139,"phases":140,"primaryCompletion":64,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},"RECRUITING",[79],"2027-10-10","2024-09-20",30,[145],"Prostate Cancer (Post Prostatectomy)",[65],{"trials":148,"activeCount":89},[],{"trials":150,"activeCount":89},[],{"trials":152,"activeCount":89},[],{"intervention":75,"totalTrials":85,"cells":154},{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":167,"PHASE4":169,"NA":171},{"trials":156,"activeCount":89},[],{"trials":158,"activeCount":89},[],{"trials":160,"activeCount":85,"soonestReadout":74},[161],{"nctId":72,"briefTitle":73,"status":99,"phases":162,"primaryCompletion":74,"completion":74,"start":54,"enrollment":163,"conditions":164,"interventions":166},[79],75,[165,22],"Type 1 Diabetes",[75],{"trials":168,"activeCount":89},[],{"trials":170,"activeCount":89},[],{"trials":172,"activeCount":89},[],{"intervention":41,"totalTrials":174,"cells":175},3,{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":213},{"trials":177,"activeCount":89},[],{"trials":179,"activeCount":11,"soonestReadout":40},[180,188,194],{"nctId":38,"briefTitle":39,"status":181,"phases":182,"primaryCompletion":40,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":187},"ACTIVE_NOT_RECRUITING",[78],"2026-12","2016-11-01",20,[17],[41],{"nctId":43,"briefTitle":44,"status":181,"phases":189,"primaryCompletion":45,"completion":190,"start":191,"enrollment":143,"conditions":192,"interventions":193},[78],"2027-02","2017-10-24",[17],[41,41],{"nctId":195,"briefTitle":196,"status":197,"phases":198,"primaryCompletion":199,"completion":200,"start":201,"enrollment":25,"conditions":202,"interventions":204},"NCT02237053","Effects of Glucagon Administration on Energy Expenditure","COMPLETED",[78],"2015-06","2016-06","2014-09",[203,17],"Hyperglucagonemia",[41,205,206],"Octreotide","Insulin",{"trials":208,"activeCount":89},[],{"trials":210,"activeCount":89},[],{"trials":212,"activeCount":89},[],{"trials":214,"activeCount":89},[],{"intervention":55,"totalTrials":85,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":230,"PHASE3":232,"PHASE4":234,"NA":236},{"trials":218,"activeCount":89},[],{"trials":220,"activeCount":85,"soonestReadout":54},[221],{"nctId":52,"briefTitle":53,"status":139,"phases":222,"primaryCompletion":54,"completion":54,"start":223,"enrollment":143,"conditions":224,"interventions":228},[78],"2024-10-22",[225,226,227],"Prostate CA","Prostate Cancer (Adenocarcinoma)","Prostate Cancer Surgery",[55,229],"Relugolix",{"trials":231,"activeCount":89},[],{"trials":233,"activeCount":89},[],{"trials":235,"activeCount":89},[],{"trials":237,"activeCount":89},[],{"intervention":229,"totalTrials":85,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":248,"PHASE3":250,"PHASE4":252,"NA":254},{"trials":241,"activeCount":89},[],{"trials":243,"activeCount":85,"soonestReadout":54},[244],{"nctId":52,"briefTitle":53,"status":139,"phases":245,"primaryCompletion":54,"completion":54,"start":223,"enrollment":143,"conditions":246,"interventions":247},[78],[225,226,227],[55,229],{"trials":249,"activeCount":89},[],{"trials":251,"activeCount":89},[],{"trials":253,"activeCount":89},[],{"trials":255,"activeCount":89},[],{"intervention":50,"totalTrials":85,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":259,"activeCount":89},[],{"trials":261,"activeCount":85,"soonestReadout":49},[262],{"nctId":47,"briefTitle":48,"status":181,"phases":263,"primaryCompletion":49,"completion":183,"start":264,"enrollment":265,"conditions":266,"interventions":268},[78],"2023-03-16",9,[267],"Ketones, Metabolism",[50],{"trials":270,"activeCount":89},[],{"trials":272,"activeCount":89},[],{"trials":274,"activeCount":89},[],{"trials":276,"activeCount":89},[],{"intervention":278,"totalTrials":11,"cells":279},"octreotide",{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":306},{"trials":281,"activeCount":89},[],{"trials":283,"activeCount":89},[284],{"nctId":195,"briefTitle":196,"status":197,"phases":285,"primaryCompletion":199,"completion":200,"start":201,"enrollment":25,"conditions":286,"interventions":287},[78],[203,17],[41,205,206],{"trials":289,"activeCount":89},[],{"trials":291,"activeCount":89},[],{"trials":293,"activeCount":89},[294],{"nctId":295,"briefTitle":296,"status":297,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT02032784","Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding","TERMINATED",[81],"2018-06-28","2020-07-06","2014-03",33,[304],"Adenoma",[278],{"trials":307,"activeCount":89},[],{"intervention":309,"totalTrials":85,"cells":310},"Liposomal Bupivacaine",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":334},{"trials":312,"activeCount":89},[],{"trials":314,"activeCount":89},[],{"trials":316,"activeCount":89},[],{"trials":318,"activeCount":89},[],{"trials":320,"activeCount":89},[321],{"nctId":322,"briefTitle":323,"status":197,"phases":324,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":332},"NCT02352922","Randomized Trial of Wound Infiltration With Extended-release Bupivacaine Before Laparoscopic or Robotic Hysterectomy",[81],"2016-01","2016-02","2015-07",64,[330,331],"Pain, Postoperative","Surgical Procedure, Unspecified",[309,333],"Bupivacaine HCl",{"trials":335,"activeCount":89},[],{"intervention":333,"totalTrials":85,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":344,"PHASE4":346,"NA":352},{"trials":339,"activeCount":89},[],{"trials":341,"activeCount":89},[],{"trials":343,"activeCount":89},[],{"trials":345,"activeCount":89},[],{"trials":347,"activeCount":89},[348],{"nctId":322,"briefTitle":323,"status":197,"phases":349,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":350,"interventions":351},[81],[330,331],[309,333],{"trials":353,"activeCount":89},[],{"intervention":355,"totalTrials":85,"cells":356},"Intravenous Acetaminophen",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":375},{"trials":358,"activeCount":89},[],{"trials":360,"activeCount":89},[],{"trials":362,"activeCount":89},[],{"trials":364,"activeCount":89},[],{"trials":366,"activeCount":89},[367],{"nctId":368,"briefTitle":369,"status":197,"phases":370,"primaryCompletion":327,"completion":327,"start":371,"enrollment":372,"conditions":373,"interventions":374},"NCT02025634","Intravenous Acetaminophen for Non-Narcotic Postoperative Pain Management Following Knee Arthroscopy",[81],"2013-11",119,[330],[355],{"trials":376,"activeCount":89},[],{"intervention":378,"totalTrials":85,"cells":379},"prednisone",{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":386,"PHASE4":388,"NA":398},{"trials":381,"activeCount":89},[],{"trials":383,"activeCount":89},[],{"trials":385,"activeCount":89},[],{"trials":387,"activeCount":89},[],{"trials":389,"activeCount":89},[390],{"nctId":391,"briefTitle":392,"status":297,"phases":393,"primaryCompletion":394,"completion":394,"start":301,"enrollment":174,"conditions":395,"interventions":397},"NCT02039115","Reduction in Symptomatic Esophageal Stricture Formation",[81],"2015-02",[396],"Esophageal Stenosis",[378],{"trials":399,"activeCount":89},[],{"intervention":401,"totalTrials":85,"cells":402},"Fluorescein Sodium",{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":426},{"trials":404,"activeCount":89},[],{"trials":406,"activeCount":89},[],{"trials":408,"activeCount":89},[],{"trials":410,"activeCount":89},[],{"trials":412,"activeCount":89},[413],{"nctId":414,"briefTitle":415,"status":416,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":425},"NCT02478346","Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions","UNKNOWN",[81],"2018-12","2019-04","2015-05",200,[423,424],"Cerebrovascular Disorders","Intracranial Neoplasms",[401],{"trials":427,"activeCount":89},[],{"intervention":429,"totalTrials":85,"cells":430},"Preop acetaminophen IV",{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":439,"NA":458},{"trials":432,"activeCount":89},[],{"trials":434,"activeCount":89},[],{"trials":436,"activeCount":89},[],{"trials":438,"activeCount":89},[],{"trials":440,"activeCount":89},[441],{"nctId":442,"briefTitle":443,"status":197,"phases":444,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":450},"NCT02449369","Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee",[81],"2016-09","2015-04",180,[449],"Unilateral Knee Arthroplasty",[429,451,452,453,454,455,456,457],"Preop orphenadrine IV","Postop oral oxycodone & acetaminophen","Postop hydromorphone IV","Postop oral orphenadrine","Postop oral oxycodone","Postop acetaminophen IV","Postop orphenadrine IV",{"trials":459,"activeCount":89},[],{"intervention":451,"totalTrials":85,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":476},{"trials":463,"activeCount":89},[],{"trials":465,"activeCount":89},[],{"trials":467,"activeCount":89},[],{"trials":469,"activeCount":89},[],{"trials":471,"activeCount":89},[472],{"nctId":442,"briefTitle":443,"status":197,"phases":473,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":474,"interventions":475},[81],[449],[429,451,452,453,454,455,456,457],{"trials":477,"activeCount":89},[],{"intervention":452,"totalTrials":85,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":494},{"trials":481,"activeCount":89},[],{"trials":483,"activeCount":89},[],{"trials":485,"activeCount":89},[],{"trials":487,"activeCount":89},[],{"trials":489,"activeCount":89},[490],{"nctId":442,"briefTitle":443,"status":197,"phases":491,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":492,"interventions":493},[81],[449],[429,451,452,453,454,455,456,457],{"trials":495,"activeCount":89},[],{"intervention":453,"totalTrials":85,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":512},{"trials":499,"activeCount":89},[],{"trials":501,"activeCount":89},[],{"trials":503,"activeCount":89},[],{"trials":505,"activeCount":89},[],{"trials":507,"activeCount":89},[508],{"nctId":442,"briefTitle":443,"status":197,"phases":509,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":510,"interventions":511},[81],[449],[429,451,452,453,454,455,456,457],{"trials":513,"activeCount":89},[],{"intervention":454,"totalTrials":85,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":530},{"trials":517,"activeCount":89},[],{"trials":519,"activeCount":89},[],{"trials":521,"activeCount":89},[],{"trials":523,"activeCount":89},[],{"trials":525,"activeCount":89},[526],{"nctId":442,"briefTitle":443,"status":197,"phases":527,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":528,"interventions":529},[81],[449],[429,451,452,453,454,455,456,457],{"trials":531,"activeCount":89},[],{"intervention":455,"totalTrials":85,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":548},{"trials":535,"activeCount":89},[],{"trials":537,"activeCount":89},[],{"trials":539,"activeCount":89},[],{"trials":541,"activeCount":89},[],{"trials":543,"activeCount":89},[544],{"nctId":442,"briefTitle":443,"status":197,"phases":545,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":546,"interventions":547},[81],[449],[429,451,452,453,454,455,456,457],{"trials":549,"activeCount":89},[],{"intervention":456,"totalTrials":85,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":566},{"trials":553,"activeCount":89},[],{"trials":555,"activeCount":89},[],{"trials":557,"activeCount":89},[],{"trials":559,"activeCount":89},[],{"trials":561,"activeCount":89},[562],{"nctId":442,"briefTitle":443,"status":197,"phases":563,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":564,"interventions":565},[81],[449],[429,451,452,453,454,455,456,457],{"trials":567,"activeCount":89},[],{"intervention":457,"totalTrials":85,"cells":569},{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":578,"NA":584},{"trials":571,"activeCount":89},[],{"trials":573,"activeCount":89},[],{"trials":575,"activeCount":89},[],{"trials":577,"activeCount":89},[],{"trials":579,"activeCount":89},[580],{"nctId":442,"briefTitle":443,"status":197,"phases":581,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":582,"interventions":583},[81],[449],[429,451,452,453,454,455,456,457],{"trials":585,"activeCount":89},[],{"intervention":587,"totalTrials":85,"cells":588},"BioDFence G3",{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":595,"PHASE4":611,"NA":613},{"trials":590,"activeCount":89},[],{"trials":592,"activeCount":89},[],{"trials":594,"activeCount":89},[],{"trials":596,"activeCount":89},[597],{"nctId":598,"briefTitle":599,"status":600,"phases":601,"primaryCompletion":602,"completion":603,"start":604,"enrollment":89,"conditions":605,"interventions":610},"NCT05363644","BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy","WITHDRAWN",[80],"2023-12-31","2024-06-30","2023-04-01",[606,607,608,609],"Prostate Cancer","Prostatectomy","Erectile Dysfunction Following Radical Prostatectomy","Incontinence, Urinary",[587],{"trials":612,"activeCount":89},[],{"trials":614,"activeCount":89},[],{"intervention":616,"totalTrials":85,"cells":617},"Tisseel Injectable Product",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":619,"activeCount":89},[],{"trials":621,"activeCount":89},[],{"trials":623,"activeCount":89},[624],{"nctId":625,"briefTitle":626,"status":600,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":89,"conditions":630,"interventions":632},"NCT05264922","Stromal Vascular Fraction (SVF) Cells for Non-Operative Treatment of Small Rotator Cuff Tears",[79],"2022-07-22","2022-01-09",[631],"Rotator Cuff Tears",[616,633],"Stromal Vascular Fraction Cells",{"trials":635,"activeCount":89},[],{"trials":637,"activeCount":89},[],{"trials":639,"activeCount":89},[],{"intervention":633,"totalTrials":85,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":652,"PHASE4":654,"NA":656},{"trials":643,"activeCount":89},[],{"trials":645,"activeCount":89},[],{"trials":647,"activeCount":89},[648],{"nctId":625,"briefTitle":626,"status":600,"phases":649,"primaryCompletion":628,"completion":628,"start":629,"enrollment":89,"conditions":650,"interventions":651},[79],[631],[616,633],{"trials":653,"activeCount":89},[],{"trials":655,"activeCount":89},[],{"trials":657,"activeCount":89},[],{"intervention":659,"totalTrials":85,"cells":660},"inhaled nitric oxide",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":662,"activeCount":89},[],{"trials":664,"activeCount":89},[],{"trials":666,"activeCount":89},[667],{"nctId":668,"briefTitle":669,"status":297,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":677},"NCT03576885","Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia",[78,79],"2023-10-09","2019-07-15",32,[675,676],"Pulmonary Hypertension","Bronchopulmonary Dysplasia",[659],{"trials":679,"activeCount":89},[],{"trials":681,"activeCount":89},[],{"trials":683,"activeCount":89},[],{"intervention":685,"totalTrials":85,"cells":686},"avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":688,"activeCount":89},[],{"trials":690,"activeCount":89},[],{"trials":692,"activeCount":89},[693],{"nctId":694,"briefTitle":695,"status":600,"phases":696,"primaryCompletion":697,"completion":698,"start":699,"enrollment":89,"conditions":700,"interventions":703},"NCT05574504","Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy",[79],"2026-11","2028-11","2023-05-08",[701,702],"Metastatic Cancer","Urothelial Carcinoma",[685],{"trials":705,"activeCount":89},[],{"trials":707,"activeCount":89},[],{"trials":709,"activeCount":89},[],{"intervention":711,"totalTrials":85,"cells":712},"Study Medication",{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":714,"activeCount":89},[],{"trials":716,"activeCount":89},[],{"trials":718,"activeCount":89},[719],{"nctId":720,"briefTitle":721,"status":197,"phases":722,"primaryCompletion":723,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":728},"NCT04432090","GPR119 Agonist for Hypoglycemia in Type 1 Diabetes",[79],"2023-08-12","2021-04-21",110,[727],"Diabetes Mellitus, Type 1",[711],{"trials":730,"activeCount":89},[],{"trials":732,"activeCount":89},[],{"trials":734,"activeCount":89},[],{"intervention":736,"totalTrials":85,"cells":737},"Continous IV infusion of Nesiritide",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":739,"activeCount":89},[],{"trials":741,"activeCount":89},[742],{"nctId":743,"briefTitle":744,"status":197,"phases":745,"primaryCompletion":746,"completion":747,"start":748,"enrollment":25,"conditions":749,"interventions":750},"NCT03234751","Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects",[78],"2018-09-24","2020-02-19","2017-07-13",[24],[736,751],"Hyperinsulinemic euglycemic clamp",{"trials":753,"activeCount":89},[],{"trials":755,"activeCount":89},[],{"trials":757,"activeCount":89},[],{"trials":759,"activeCount":89},[],{"intervention":751,"totalTrials":85,"cells":761},{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":770,"PHASE3":772,"PHASE4":774,"NA":776},{"trials":763,"activeCount":89},[],{"trials":765,"activeCount":89},[766],{"nctId":743,"briefTitle":744,"status":197,"phases":767,"primaryCompletion":746,"completion":747,"start":748,"enrollment":25,"conditions":768,"interventions":769},[78],[24],[736,751],{"trials":771,"activeCount":89},[],{"trials":773,"activeCount":89},[],{"trials":775,"activeCount":89},[],{"trials":777,"activeCount":89},[],{"intervention":779,"totalTrials":85,"cells":780},"Nesiritide",{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":796,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":782,"activeCount":89},[],{"trials":784,"activeCount":89},[785],{"nctId":786,"briefTitle":787,"status":197,"phases":788,"primaryCompletion":789,"completion":790,"start":371,"enrollment":33,"conditions":791,"interventions":794},"NCT01977859","BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects",[78],"2016-02-15","2017-02-28",[17,792,793,24],"Cardiovascular Disease","Hypertension",[779,795],"Saline",{"trials":797,"activeCount":89},[],{"trials":799,"activeCount":89},[],{"trials":801,"activeCount":89},[],{"trials":803,"activeCount":89},[],{"intervention":795,"totalTrials":85,"cells":805},{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":814,"PHASE3":816,"PHASE4":818,"NA":820},{"trials":807,"activeCount":89},[],{"trials":809,"activeCount":89},[810],{"nctId":786,"briefTitle":787,"status":197,"phases":811,"primaryCompletion":789,"completion":790,"start":371,"enrollment":33,"conditions":812,"interventions":813},[78],[17,792,793,24],[779,795],{"trials":815,"activeCount":89},[],{"trials":817,"activeCount":89},[],{"trials":819,"activeCount":89},[],{"trials":821,"activeCount":89},[],{"intervention":206,"totalTrials":85,"cells":823},{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":832,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":825,"activeCount":89},[],{"trials":827,"activeCount":89},[828],{"nctId":195,"briefTitle":196,"status":197,"phases":829,"primaryCompletion":199,"completion":200,"start":201,"enrollment":25,"conditions":830,"interventions":831},[78],[203,17],[41,205,206],{"trials":833,"activeCount":89},[],{"trials":835,"activeCount":89},[],{"trials":837,"activeCount":89},[],{"trials":839,"activeCount":89},[],{"intervention":841,"totalTrials":85,"cells":842},"BPM31510",{"EARLY_PHASE1":843,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":844,"activeCount":89},[845],{"nctId":846,"briefTitle":847,"status":600,"phases":848,"primaryCompletion":849,"completion":849,"start":850,"enrollment":89,"conditions":851,"interventions":853},"NCT04999488","Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia",[77],"2024-12","2023-12",[852],"Sarcopenia",[841],{"trials":855,"activeCount":89},[],{"trials":857,"activeCount":89},[],{"trials":859,"activeCount":89},[],{"trials":861,"activeCount":89},[],{"trials":863,"activeCount":89},[],{"intervention":865,"totalTrials":85,"cells":866},"Phentermine",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":873,"PHASE4":875,"NA":877},{"trials":868,"activeCount":89},[],{"trials":870,"activeCount":89},[],{"trials":872,"activeCount":89},[],{"trials":874,"activeCount":89},[],{"trials":876,"activeCount":89},[],{"trials":878,"activeCount":89},[879],{"nctId":880,"briefTitle":881,"status":197,"phases":882,"primaryCompletion":883,"completion":883,"start":884,"enrollment":885,"conditions":886,"interventions":889},"NCT01616082","Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)",[82],"2012-11","2011-09",39,[17,887,888],"Overweight","Metabolic Diseases",[865],{"intervention":891,"totalTrials":85,"cells":892},"Short-term ON-Q",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":901,"NA":903},{"trials":894,"activeCount":89},[],{"trials":896,"activeCount":89},[],{"trials":898,"activeCount":89},[],{"trials":900,"activeCount":89},[],{"trials":902,"activeCount":89},[],{"trials":904,"activeCount":89},[905],{"nctId":906,"briefTitle":907,"status":197,"phases":908,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":913,"interventions":915},"NCT03245359","Pain Management After TKA: Comparison of Short- and Long-term Nerve Blocks",[82],"2019-01-08","2019-05-20","2017-09-28",50,[914,330],"Anesthesia, Local",[891,916],"Long-term ON-Q",{"intervention":916,"totalTrials":85,"cells":918},{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":925,"PHASE4":927,"NA":929},{"trials":920,"activeCount":89},[],{"trials":922,"activeCount":89},[],{"trials":924,"activeCount":89},[],{"trials":926,"activeCount":89},[],{"trials":928,"activeCount":89},[],{"trials":930,"activeCount":89},[931],{"nctId":906,"briefTitle":907,"status":197,"phases":932,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":933,"interventions":934},[82],[914,330],[891,916],{"intervention":936,"totalTrials":85,"cells":937},"SARSCoV2 Convalescent Plasma",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":948},{"trials":939,"activeCount":89},[],{"trials":941,"activeCount":89},[],{"trials":943,"activeCount":89},[],{"trials":945,"activeCount":89},[],{"trials":947,"activeCount":89},[],{"trials":949,"activeCount":89},[950],{"nctId":951,"briefTitle":952,"status":953,"phases":954,"conditions":955,"interventions":957},"NCT04374370","SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)","NO_LONGER_AVAILABLE",[],[956,936],"COVID",[936]]